Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

MannKind (MNKD) Stock Price & Analysis

2,105 Followers

MNKD Stock Chart & Stats

$4.13-$0.03(-0.72%)
At close: 4:00 PM EST
$3$3.5$4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$4.08 - $4.18
52-Week Range
$2.23 - $6.51
Previous Close
$4.16
Volume
N/A
Average Volume (3M)
3.64M
Market Cap
$1.34B
Enterprise Value
$1.59B
Total Cash (Recent Filing)
$96.61M
Total Debt (Recent Filing)
$433.52M
Price to Earnings (P/E)
―
Beta
1.15
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
0.01
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Sustained double-digit revenue growth indicates expanding commercial adoption across MannKind’s portfolio rather than dependence on a single stagnant product. Continued top-line momentum can support operating leverage, broaden the revenue base, and strengthen the company’s ability to fund product and pipeline development.

High Gross Margins

Consistently high gross margins demonstrate attractive product-level economics and provide a meaningful foundation for future operating leverage. If revenue growth continues, the margin profile gives MannKind greater potential to absorb commercial investment, support profitability, and generate cash from an expanding product base.

Diversified Commercial And Pipeline Base

A broader commercial and development portfolio reduces reliance on any one product and creates multiple avenues for future growth. Royalty income, partnered assets, and wholly owned inhaled therapies can diversify revenue sources while extending the value of MannKind’s Technosphere platform.

Bears Say

Stressed Balance Sheet

Persistent negative equity and sizable debt reduce financial flexibility and make the capital structure more vulnerable to execution setbacks. Leverage can constrain investment in commercialization and development, while refinancing or additional capital needs could limit management’s strategic options over the next several quarters.

Renewed Cash Burn

The return to negative operating and free cash flow shows that recent profitability has not yet translated into consistently self-funded operations. Continued cash-flow volatility could require external financing, restrict investment capacity, and weaken confidence that revenue growth will produce durable financial independence.

Afrezza Adult Execution Weakness

Weak adult Afrezza execution highlights commercial concentration in pediatric growth and Furoscix while reducing the contribution of an established product. Field turnover, competitive pressure, and lower promotional focus may limit brand expansion and make overall portfolio growth more dependent on newer launches.

MannKind News

MNKD FAQ

What was MannKind’s price range in the past 12 months?
MannKind lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is MannKind’s market cap?
MannKind’s market cap is $1.34B.
When is MannKind’s upcoming earnings report date?
MannKind’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 102 days.
How were MannKind’s earnings last quarter?
MannKind released its earnings results on Nov 05, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.066 by -$0.004.
Is MannKind overvalued?
According to Wall Street analysts MannKind’s price is currently Undervalued.
Does MannKind pay dividends?
MannKind does not currently pay dividends.
What is MannKind’s EPS estimate?
MannKind’s EPS estimate is 0.01.
How many shares outstanding does MannKind have?
MannKind has 321,640,100 shares outstanding.
What happened to MannKind’s price movement after its last earnings report?
MannKind reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.066. Following the earnings report the stock price went up 3.723%.
Which hedge fund is a major shareholder of MannKind?
Hedge funds hold MannKind shares: the largest hedge-fund position in MannKind is 72,325,762 shares, and hedge funds increased their holdings by 2.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology